Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma
ShareXFacebook

(MedPage Today) -- CHICAGO -- Teclistamab (Tecvayli) monotherapy significantly improved survival compared with standard therapies in patients with multiple myeloma who had received up to three previous lines of therapy, the phase III MajesTEC...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Advertisement